Ovarian cancer screening: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) No edit summary |
||
| Line 11: | Line 11: | ||
*The reason of increased [[mortality]] and late detection of [[ovarian cancer]] in its advanced stage is because the [[screening]] systems that are being used have poor or limited [[sensitivity]] and [[specificity]]<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref>. | *The reason of increased [[mortality]] and late detection of [[ovarian cancer]] in its advanced stage is because the [[screening]] systems that are being used have poor or limited [[sensitivity]] and [[specificity]]<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref>. | ||
*[[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of ealy detection of [[ovarian cancer]] but this is stil an emerging proof. | *[[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of ealy detection of [[ovarian cancer]] but this is stil an emerging proof. | ||
*Examples of screening and diagnostic methods for ovarian cancer include: | *Examples of [[screening]] and [[diagnostic]] methods for [[ovarian cancer]] include: | ||
**Pelvic examination | **[[Pelvic examination]] | ||
**Cancer antigen 125 (CA 125) tumor marker | **[[Cancer antigen 125]] ([[CA 125]]) [[tumor marker]] | ||
**Transvaginal ultrasound (TVU) | **Transvaginal ultrasound (TVU) | ||
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | **Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | ||
Revision as of 18:08, 12 July 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer screening On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer screening |
|
Risk calculators and risk factors for Ovarian cancer screening |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis[1]
- Ovarian cancer is the fifth most common cause of cancer-related mortality in women
- 75% of women with ovarian cancer are diagnosed in an advanced stage
- Ovarian cancer is the most lethal gynecological cancer[2]
- The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used have poor or limited sensitivity and specificity[1].
- Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof.
- Examples of screening and diagnostic methods for ovarian cancer include:
- Pelvic examination
- Cancer antigen 125 (CA 125) tumor marker
- Transvaginal ultrasound (TVU)
- Multimarker panels and bioinformatic analysis of proteomic patterns[2]
References
- ↑ 1.0 1.1 Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
- ↑ 2.0 2.1 Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.